Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient

Details for Australian Patent Application No. 2002327097 (hide)

International Classifications

Event Publications

23 January 2003 Complete Application Filed

Priority application(s): 2001-247055 16.08.01 JP

29 May 2003 Application Open to Public Inspection

Published as AU-B-2002327097

3 November 2005 Change of Name(s) of Applicant(s), Section 104

Daiichi Suntory Pharma Co., Ltd.; Japan as represented by President of National Centre of Neurology and Psychiatry The name of the applicant has been changed to Daiichi Asubio Pharma Co., Ltd.; Japan as represented by President of National Centre of Neurology and Psychiatry

24 May 2007 Application Accepted

Published as AU-B-2002327097

21 June 2007 Change of Name(s) of Applicant(s), Section 104

Japan as represented by President of National Centre of Neurology and Psychiatry; Daiichi Asubio Pharma Co., Ltd. The name of the applicant has been changed to Japan as represented by President of National Centre of Neurology and Psychiatry; Asubio Pharma Co., Ltd.

20 September 2007 Standard Patent Sealed

29 April 2010 Assignment Registered

Japan as represented by President of National Centre of Neurology and Psychiatry; Asubio Pharma Co., Ltd. The patent has been assigned to Japan as represented by President of National Centre of Neurology and Psychiatry

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.